Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in
parallel with obesity and type 2 diabetes. Aim To review the global epidemiology of NAFLD …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

Despite the substantial gains in our understanding of NAFLD/NASH over the past 2
decades, there has been some dissatisfaction with the terminology “non‐alcoholic” which …

As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence
of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of …

Background & Aims Aldafermin, an engineered analog of fibroblast growth factor 19, inhibits
bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week …

OBJECTIVE To evaluate whether the sodium–glucose cotransporter 2 inhibitor
empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well …

Non-alcoholic fatty liver disease is a very common medical condition, driven by a
combination of genetic and lifestyle factors, ultimately producing a severe chronic liver …

Background and Aims Manual histological assessment is currently the accepted standard for
diagnosing and monitoring disease progression in NASH, but is limited by variability in …

Background Glucagon‐like peptide‐1 receptor agonists may be a treatment option in
patients with non‐alcoholic fatty liver disease (NAFLD). Aims To investigate the effects of …